Posted On: 5/29/2020 10:55 AM
Merck 641- A Phase 3 trial of Pembrolizumab and Enzalutamide.
MCRPC treatment naïve
Sponsored by: Merck
Please contact one of our Clinical Research Coordinators today to find out more information if you are interested in this trial.
Research Department (315) 478-4185, option 3